The use of recombinant galectin-9 in rats with adjuvant-induced arthritis inhibited inflammatory bone destruction, indicating that exogenous galectin-9 has therapeutic potential in patients with RA.188. Here, LGALS9 is linked to rheumatoid arthritis.